insights_auto
Why is ROIV down 2.09%?
Dive Deeperchevron_right
ROIV:NASDAQ
Roivant Sciences Ltd
$37.42
arrow_downward
-2.09%(-0.80) 1D
Sep 23, 2:47:24 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$38.00
High
$38.47
Low
$37.19
Mkt. cap
27.03B
Avg. vol.
8.88M
Volume
2.65M
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$38.00
High
$38.47
Low
$37.19
Mkt. cap
27.03B
Avg. vol.
8.88M
Volume
2.65M
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Benzinga
·
5 hours ago
Immunovant Ends Autoimmune Skin Disorder Program
Benzinga
·
5 hours ago
Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)
Seeking Alpha
·
7 hours ago
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ)
Stock Titan
·
7 hours ago
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it.
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd